Diabetes drug Mounjaro drives record sales and share price highs for Eli Lilly on potential as obesity treatment

Eli Lilly's diabetes drug Mounjaro exceeded sales expectations, generating nearly $1 billion in second quarter revenue.
Mounjaro is driving strong growth for Eli Lilly, with its stock reaching record highs due to the drug's potential approval for treating obesity.
Demand for Mounjaro in the US has led to delays in filling orders, though Eli Lilly expects supply constraints to ease.
Eli Lilly raised its full year revenue guidance on Mounjaro's performance, now expecting up to $33.9 billion.
Novo Nordisk also saw its stock reach new highs following promising results for its obesity drug Wegovy in clinical trials.